Roquefort Therapeutics (LSE:ROQ) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Days Payable?

Roquefort Therapeutics's average Accounts Payable for the six months ended in Dec. 2023 was £0.21 Mil. Roquefort Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was £0.00 Mil.

The historical rank and industry rank for Roquefort Therapeutics's Days Payable or its related term are showing as below:

LSE:ROQ's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.01
* Ranked among companies with meaningful Days Payable only.

Roquefort Therapeutics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Roquefort Therapeutics Days Payable Historical Data

The historical data trend for Roquefort Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Days Payable Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Days Payable	-	-	-	-	-

Competitive Comparison of Roquefort Therapeutics's Days Payable

For the Biotechnology subindustry, Roquefort Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Days Payable falls into.

Roquefort Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Roquefort Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.068	+	0.145)	/	2 )	/	0	*	365
=	0.1065					/	0	*	365
=	N/A

Roquefort Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.275	+	0.145)	/	2 )	/	0	*	365 / 2
=	0.21					/	0	*	365 / 2
=	N/A

Roquefort Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines